Penumbra, Inc. Share Price

Equities

PEN

US70975L1070

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 21:00:02 24/05/2024 BST 5-day change 1st Jan Change
193.7 USD +1.56% Intraday chart for Penumbra, Inc. -4.85% -23.01%
Sales 2024 * 1.24B 97.42B Sales 2025 * 1.44B 113B Capitalization 7.51B 589B
Net income 2024 * 107M 8.4B Net income 2025 * 150M 11.78B EV / Sales 2024 * 5.82 x
Net cash position 2024 * 289M 22.7B Net cash position 2025 * 398M 31.27B EV / Sales 2025 * 4.93 x
P/E ratio 2024 *
70.8 x
P/E ratio 2025 *
51.7 x
Employees 4,200
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.18%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.56%
1 week-4.85%
Current month-1.43%
1 month-6.06%
3 months-18.76%
6 months-16.85%
Current year-23.01%
More quotes
1 week
190.58
Extreme 190.58
204.12
1 month
190.58
Extreme 190.58
220.41
Current year
190.58
Extreme 190.58
277.34
1 year
180.93
Extreme 180.93
348.67
3 years
114.87
Extreme 114.865
348.67
5 years
114.87
Extreme 114.865
348.67
10 years
35.32
Extreme 35.315
348.67
More quotes
Managers TitleAgeSince
Founder 62 20/06/04
Chief Executive Officer 62 20/06/04
Director of Finance/CFO 52 01/12/19
Members of the board TitleAgeSince
Director/Board Member 60 12/01/17
Director/Board Member 57 31/03/15
Chief Executive Officer 62 20/06/04
More insiders
Date Price Change Volume
24/05/24 193.7 +1.56% 193,348
23/05/24 190.7 -4.16% 247,586
22/05/24 199 -0.63% 170,699
21/05/24 200.2 -0.60% 166,696
20/05/24 201.4 -1.03% 166,823

Delayed Quote Nyse, May 24, 2024 at 09:00 pm

More quotes
Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
193.7 USD
Average target price
270.8 USD
Spread / Average Target
+39.85%
Consensus